Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
Zobair M. Younossi, Pegah Golabi, James M. Paik, et al.
Hepatology (2023) Vol. 77, Iss. 4, pp. 1335-1347
Open Access | Times Cited: 1312

Showing 1-25 of 1312 citing articles:

Hepatic inflammatory responses in liver fibrosis
Linda Hammerich, Frank Tacke
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 633-646
Closed Access | Times Cited: 282
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 271
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2024), pp. gutjnl-330595
Open Access | Times Cited: 220
The Global Burden of Liver Disease
Zobair M. Younossi, Grace Lai‐Hung Wong, Quentin M. Anstee, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 1978-1991
Open Access | Times Cited: 195
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Rohit Loomba, Arun J. Sanyal, Kris V. Kowdley, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 11, pp. 998-1008
Open Access | Times Cited: 193
Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 169
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 146
Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten?
Chrysi Koliaki, Μaria Dalamaga, Stavros Liatis
Current Obesity Reports (2023) Vol. 12, Iss. 4, pp. 514-527
Open Access | Times Cited: 134
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
Zobair M. Younossi, James M. Paik, Maria Stepanova, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 5, pp. 694-701
Closed Access | Times Cited: 122
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
Gong Feng, Luca Valenti, Vincent Wai‐Sun Wong, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 46-56
Closed Access | Times Cited: 91
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 4, pp. 888-897
Open Access | Times Cited: 90
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review
Julia Wattacheril, Manal F. Abdelmalek, Joseph K. Lim, et al.
Gastroenterology (2023) Vol. 165, Iss. 4, pp. 1080-1088
Open Access | Times Cited: 90
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 90
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 82
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Hyeok‐Hee Lee, Han Ah Lee, Eun-Jin Kim, et al.
Gut (2023), pp. gutjnl-331003
Closed Access | Times Cited: 80
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
Alina M. Allen, Jeffrey V. Lazarus, Zobair M. Younossi
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 209-217
Open Access | Times Cited: 76
The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
James M. Paik, Linda Henry, Youssef Younossi, et al.
Hepatology Communications (2023) Vol. 7, Iss. 10
Open Access | Times Cited: 76
A global research priority agenda to advance public health responses to fatty liver disease
Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 618-634
Open Access | Times Cited: 68
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
Daniel Q. Huang, Nabil Noureddin, Veeral Ajmera, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 9, pp. 829-836
Open Access | Times Cited: 67
Human trials exploring anti-aging medicines
Leonard Guarente, David Sinclair, Guido Kroemer
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 354-376
Open Access | Times Cited: 60
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Salvatore Petta, Giovanni Targher, Stefano Romeo, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1526-1536
Open Access | Times Cited: 56
Global burden of metabolic diseases, 1990–2021
Huai Zhang, Xiaodong Zhou, Michael D. Shapiro, et al.
Metabolism (2024) Vol. 160, pp. 155999-155999
Closed Access | Times Cited: 56
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 10, pp. 1999-2010.e8
Closed Access | Times Cited: 55
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2023) Vol. 95, pp. 101231-101231
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top